{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-103150","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.483004+00:00","generated_at":"2026-05-15T13:49:47.993236+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xilio Therapeutics announces 1-for-14 reverse stock split to regain Nasdaq compliance","bullets":["Effective 5:00 p.m. ET on March 13, 2026; trading on split-adjusted basis starts March 16 under ticker XLO.","Outstanding shares reduce from ~73.5M to ~5.2M; authorized shares and par value unchanged.","Purpose is to increase per-share price to meet Nasdaq minimum $1.00 bid requirement.","No fractional shares issued; stockholders receiving cash in lieu of fractional shares.","Stockholders approved reverse split at Special Meeting held February 23, 2026; ratio set by Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-103150","json":"https://secwatch.observer/filing/0001193125-26-103150.json","markdown":"https://secwatch.observer/filing/0001193125-26-103150.md","text":"https://secwatch.observer/filing/0001193125-26-103150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/xlo-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:49:47.993236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e52caf3232930681e0ad73536264cbfa6f1dd56f","claim":"Xilio Therapeutics, Inc.: Filed a Certificate of Amendment to effect a 1-for-14 reverse stock split of common stock (effective 2026-03-13).","evidence_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001731122-26-000682","ticker":"SDOT","company_name":"Sadot Group Inc.","filed_at":"2026-05-06T23:59:59+00:00","headline":"Nasdaq notifies Sadot Group of stockholders' equity deficiency; delisting risk","event_type":"regulatory","sec_items":["3.01","5.03","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000682","json":"https://secwatch.observer/filing/0001731122-26-000682.json","markdown":"https://secwatch.observer/filing/0001731122-26-000682.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701756/000173112226000682/0001731122-26-000682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701756/000173112226000682/e7614_8-k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","comparable_excerpt":"On or about May 1, 2026, the Company filed a Certificate of Amendment to Designation - After Issuance of Class or Series with the Secretary of State of the State of Nevada amending the provisions of its Articles of Incorporation regarding authorized capital stock.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1701756/000173112226000682/0001731122-26-000682-index.htm"}},{"accession":"0001731122-26-000668","ticker":"SBEV","company_name":"SPLASH BEVERAGE GROUP, INC.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M","event_type":"regulatory","sec_items":["1.01","1.02","3.01","3.02","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000668","json":"https://secwatch.observer/filing/0001731122-26-000668.json","markdown":"https://secwatch.observer/filing/0001731122-26-000668.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/e7604_8-k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","comparable_excerpt":"On May 4, 2026, the Company filed a Certificate of Withdrawal (the “Withdrawal of Designation”) with the Secretary of State of the State of Nevada and terminated the designation of its Series D Convertible Preferred Stock, par value $0.001 per share (the “Series D”). At the time of filing the Withdrawal of Designation, there were no shares of Series D issued and outstanding. The Withdrawal of Designation became effective upon filing.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm"}},{"accession":"0001628280-26-039465","ticker":"IOT","company_name":"Samsara Inc.","filed_at":"2026-06-01T20:07:41+00:00","headline":"Samsara Inc. reincorporates from Delaware to Nevada, effective June 1, 2026","event_type":"other_material","sec_items":["3.03","5.03","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: governance_change","same SEC item: 3.03, 5.03, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039465","json":"https://secwatch.observer/filing/0001628280-26-039465.json","markdown":"https://secwatch.observer/filing/0001628280-26-039465.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/0001628280-26-039465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/iot-20260601.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","comparable_excerpt":"the reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”) became effective on June 1, 2026, at 12:02 a.m. Pacific Time","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1642896/000162828026039465/0001628280-26-039465-index.htm"}},{"accession":"0001193125-26-215756","ticker":"GIG","company_name":"GigCapital7 Corp.","filed_at":"2026-05-11T23:59:59+00:00","headline":"GigCapital7 domestication from Cayman Islands to Delaware effective May 8 after shareholder vote","event_type":"other_material","sec_items":["3.03","5.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: governance_change","same SEC item: 3.03, 5.03, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215756","json":"https://secwatch.observer/filing/0001193125-26-215756.json","markdown":"https://secwatch.observer/filing/0001193125-26-215756.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023730/000119312526215756/0001193125-26-215756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023730/000119312526215756/d72988d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","comparable_excerpt":"On May 8, 2026, GigCapital7 effectuated the Domestication by filing (i) a voluntary declaration pursuant to Section 206(3) of the Companies Act (revised) of the Acts of the Cayman Islands, (ii) a certificate of corporate domestication with the Secretary of State of the State of Delaware (the “ DE SoS ”), and (iii) an interim certificate of incorporation with the DE SoS (the “ Domesticated GigCapital7 Charter ”). Domesticated GigCapital7 also adopted bylaws (the “ Domesticated GigCapital7 Bylaws ” and together with the Domesticated GigCapital7 Charter, the “ Domesticated GigCapital7 Governing Documents ”) in connection with the Domestication.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2023730/000119312526215756/0001193125-26-215756-index.htm"}},{"accession":"0001062993-26-002388","ticker":"WAMFF","company_name":"Alaska Silver Corp.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Alaska Silver simplifies capital structure, eliminates dual-class shares","event_type":"other_material","sec_items":["3.03","5.03","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: governance_change","same SEC item: 3.03, 5.03, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-002388","json":"https://secwatch.observer/filing/0001062993-26-002388.json","markdown":"https://secwatch.observer/filing/0001062993-26-002388.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1893899/000106299326002388/0001062993-26-002388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1893899/000106299326002388/form8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","comparable_excerpt":"On May 6, 2026, the Board of Directors of Alaska Silver Corp. (the \"Company\"), approved an amendment (the \"Amendment\") to the Company's Articles of the Company to eliminate its dual-class share structure by (i) eliminating its proportionate voting share class and (ii) reidentifying its subordinate voting share class as the class of \"Common Shares,\" no par value, of which the Company shall be authorized to issue an unlimited number of Common Shares.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1893899/000106299326002388/0001062993-26-002388-index.htm"}},{"accession":"0001193125-26-211978","ticker":"JPM","company_name":"JPMORGAN CHASE & CO","filed_at":"2026-05-07T23:59:59+00:00","headline":"JPMorgan issues $3B of 6.100% Fixed-Rate Reset Non-Cumulative Preferred Stock, Series PP","event_type":"other_material","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: governance_change","same SEC item: 3.03, 5.03, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-211978","json":"https://secwatch.observer/filing/0001193125-26-211978.json","markdown":"https://secwatch.observer/filing/0001193125-26-211978.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/19617/000119312526211978/0001193125-26-211978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19617/000119312526211978/d903351d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","comparable_excerpt":"On May 6, 2026, the Company filed a Certificate of Designations, Powers, Preferences and Rights with the Secretary of State of the State of Delaware, establishing the rights, preferences, privileges, qualifications, restrictions and limitations relating to the Series PP Preferred Stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/19617/000119312526211978/0001193125-26-211978-index.htm"}},{"accession":"0001829126-26-004744","ticker":"KALA","company_name":"KALA BIO, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"KALA BIO announces 1-for-50 reverse stock split effective May 8, 2026","event_type":"other_material","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: governance_change","same SEC item: 3.03, 5.03, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004744","json":"https://secwatch.observer/filing/0001829126-26-004744.json","markdown":"https://secwatch.observer/filing/0001829126-26-004744.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000182912626004744/0001829126-26-004744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000182912626004744/kalabio_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","comparable_excerpt":"On May 7, 2026, KALA BIO, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Certificate of Amendment ”) to the Company’s Restated Certificate of Incorporation (as amended, the “ Certificate of Incorporation ”) with the Secretary of State of Delaware to effect a 1-for-50 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on May 8, 2026 (the “ Reverse Stock Split ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000182912626004744/0001829126-26-004744-index.htm"}},{"accession":"0001104659-26-055632","ticker":"ENZN","company_name":"Viskase Holdings, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Viskase Holdings adopts Section 382 Rights Plan to protect NOL assets; threshold at 4.9%","event_type":"other_material","sec_items":["1.01","3.03","5.03","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: governance_change","same SEC item: 3.03, 5.03, 9.01","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-055632","json":"https://secwatch.observer/filing/0001104659-26-055632.json","markdown":"https://secwatch.observer/filing/0001104659-26-055632.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/727510/000110465926055632/0001104659-26-055632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/727510/000110465926055632/tm2613382d1_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm","comparable_excerpt":"In connection with the adoption of the Section 382 Rights Agreement, the Board approved a Certificate of Designation of Series A-2 Junior Participating Preferred Stock of Viskase Holdings, Inc. (the “Certificate of Designation”). The Certificate of Designation was filed with the Secretary of the State of Delaware on May 5, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/727510/000110465926055632/0001104659-26-055632-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}